3 assets in Metaplastic Breast Carcinoma

Therapeutic assets addressing Metaplastic Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Metaplastic Breast Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Metaplastic Breast Carcinoma	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Omega-N-Methylarginine Metaplastic Breast Carcinoma	The Methodist Hospital Research Institute	P2	CCC (53)